Skip to main content
SpringerLink
Log in

Lynch Syndrome-Associated Urological Malignancies

  • Chapter
  • First Online:
Lynch Syndrome

  • 358 Accesses

Abstract

Lynch syndrome is a hereditary cancer syndrome caused by germline alterations in mismatch repair (MMR) genes. Recently, there is growing evidence of an increased risk of development of upper tract urothelial carcinomas (UTUC) in Lynch syndrome and in fact, upper tract urothelial carcinoma has been found to be the third most common Lynch-associated malignancy. Interestingly, universal screening of UTUC exhibited that 5% of UTUC is Lynch-associated, highlighting the importance of medical and family history of UTUC patients. Several studies have suggested that Lynch patients may have an increased risk of development of bladder and prostate cancer; however, this potential association may need further investigations because of the high incidence of those cancers in general population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Baretti M, Le DT. DNA mismatch repair in cancer. Pharmacol Ther. 2018;189:45–62.

    Article  CAS  Google Scholar 

  2. Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet. 2009;41:112–7.

    Article  CAS  Google Scholar 

  3. Bonis PA, Trikalinos TA, Chung M, Chew P, Ip S, DeVine DA, Lau J. Hereditary nonpolyposis colorectal cancer: diagnostic strategies and their implications. Evid Rep Technol Assess (Full Rep). 2007:1–180.

    Google Scholar 

  4. Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F, Hill J, Evans DG. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet. 2009;75:141–9.

    Article  CAS  Google Scholar 

  5. Watson P, Riley B. The tumor spectrum in the Lynch syndrome. Familial Cancer. 2005;4:245–8.

    Article  Google Scholar 

  6. Watson P, Vasen HFA, Mecklin JP, Bernstein I, Aarnio M, Jarvinen HJ, Myrhoj T, Sunde L, Wijnen JT, Lynch HT. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008;123:444–9.

    Article  CAS  Google Scholar 

  7. Roupret M, Yates DR, Comperat E, Cussenot O. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol. 2008;54:1226–36.

    Article  Google Scholar 

  8. Barrow PJ, Ingham S, O’Hara C, Green K, McIntyre I, Lalloo F, Hill J, Evans DG. The spectrum of urological malignancy in Lynch syndrome. Familial Cancer. 2013;12:57–63.

    Article  CAS  Google Scholar 

  9. Urakami S, Inoshita N, Oka S, Miyama Y, Nomura S, Arai M, Sakaguchi K, Kurosawa K, Okaneya T. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening. Int J Urol. 2018;25:151–6.

    Article  CAS  Google Scholar 

  10. Blaszyk H, Wang L, Dietmaier W, Hofstadter F, Burgart LJ, Cheville JC, Hartmann A. Upper tract urothelial carcinoma: a clinicopathologic study including microsatellite instability analysis. Mod Pathol. 2002;15:790–7.

    Article  Google Scholar 

  11. Zhang B, Yu W, Feng X, Zhao Z, Fan Y, Meng Y, Hu S, Cui Y, He Q, Zhang H, et al. Prognostic significance of PD-L1 expression on tumor cells and tumor-infiltrating mononuclear cells in upper tract urothelial carcinoma. Med Oncol. 2017;34:94.

    Article  Google Scholar 

  12. Myrhoj T, Andersen MB, Bernstein I. Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. Familial Cancer. 2008;7:303–7.

    Article  CAS  Google Scholar 

  13. Harper HL, McKenney JK, Heald B, Stephenson A, Campbell SC, Plesec T, Magi-Galluzzi C. Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome. Mod Pathol. 2017;30:146–56.

    Article  CAS  Google Scholar 

  14. Metcalfe MJ, Petros FG, Rao P, Mork ME, Xiao L, Broaddus RR, Matin SF. Universal point of care testing for Lynch syndrome in patients with upper tract urothelial carcinoma. J Urol. 2018;199:60–5.

    Article  Google Scholar 

  15. Huang D, Matin SF, Lawrentschuk N, Roupret M. Systematic review: an update on the spectrum of urological malignancies in Lynch syndrome. Bladder Cancer. 2018;4:261–8.

    Article  Google Scholar 

  16. Kuismanen SA, Moisio AL, Schweizer P, Truninger K, Salovaara R, Arola J, Butzow R, Jiricny J, Nystrom-Lahti M, Peltomaki P. Endometrial and colorectal tumors from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. Am J Pathol. 2002;160:1953–8.

    Article  CAS  Google Scholar 

  17. Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016;22:1342–50.

    Article  CAS  Google Scholar 

  18. Mork M, Hubosky SG, Roupret M, Margulis V, Raman J, Lotan Y, O’Brien T, You N, Shariat SF, Matin SF. Lynch syndrome: a primer for urologists and panel recommendations. J Urol. 2015;194:21–9.

    Article  Google Scholar 

  19. Win AK, Lindor NM, Young JP, Macrae FA, Young GP, Williamson E, Parry S, Goldblatt J, Lipton L, Winship I, et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst. 2012;104:1363–72.

    Article  CAS  Google Scholar 

  20. Joost P, Therkildsen C, Dominguez-Valentin M, Jonsson M, Nilbert M. Urinary tract cancer in Lynch syndrome; increased risk in carriers of MSH2 mutations. Urology. 2015;86:1212–7.

    Article  Google Scholar 

  21. Skeldon SC, Semotiuk K, Aronson M, Holter S, Gallinger S, Pollett A, Kuk C, van Rhijn B, Bostrom P, Cohen Z, et al. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur Urol. 2013;63:379–85.

    Article  CAS  Google Scholar 

  22. Ryan S, Jenkins MA, Win AK. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev. 2014;23:437–49.

    Article  CAS  Google Scholar 

  23. Dominguez-Valentin M, Joost P, Therkildsen C, Jonsson M, Rambech E, Nilbert M. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. BMC Urol. 2016;16:15.

    Article  Google Scholar 

  24. Haraldsdottir S, Hampel H, Wei L, Wu C, Frankel W, Bekaii-Saab T, de la Chapelle A, Goldberg RM. Prostate cancer incidence in males with Lynch syndrome. Genet Med. 2014;16:553–7.

    Article  Google Scholar 

  25. Mayer F, Wermann H, Albers P, Stoop H, Gillis AJ, Hartmann JT, Bokemeyer CC, Oosterhuis JW, Looijenga LH, Honecker F. Histopathological and molecular features of late relapses in non-seminomas. BJU Int. 2011;107:936–43.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Yokohama City University, Yokohama, Japan

    Hisashi Hasumi & Masahiro Yao

Authors
  1. Hisashi Hasumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masahiro Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hisashi Hasumi .

Editor information

Editors and Affiliations

  1. Specially Appointed Adviser, Cancer Treatment Center, Toyonaka Municipal Hospital, Osaka, Japan

    Naohiro Tomita

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hasumi, H., Yao, M. (2020). Lynch Syndrome-Associated Urological Malignancies. In: Tomita, N. (eds) Lynch Syndrome. Springer, Singapore. https://doi.org/10.1007/978-981-15-6891-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-6891-6_7

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-6890-9

  • Online ISBN: 978-981-15-6891-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation